التفاصيل البيبلوغرافية
| العنوان: |
The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. |
| المؤلفون: |
Kempsford, Rodger D., Oliver, Amanda, Bal, Joanne, Tombs, Lee, Quinn, Dean |
| المصدر: |
Respiratory Medicine; 2013, Vol. 107 Issue 12, p1873-1880, 8p |
| مستخلص: |
Aim: To investigate the effect of time of day of dosing (morning or evening) on lung function following administration of fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg. Methods: Double-blind, placebo-controlled, randomised, three-way crossover study. Subjects with persistent asthma (N = 26) received FF/VI (morning or evening) or matching placebo once-daily for 14 (± 2 days) via dry powder inhaler (DPI). Weighted mean (0-24h) and pretreatment FEV1 (morning and evening) were determined after the Day 14 evening dose, together with mean pre-treatment (morning and evening) peak expiratory flow (PEF) on Days 2-12. Results: FF/VI 100/25 administered morning or evening produced clinically significant increases in weighted mean FEV1: the differences [95% confidence interval (CI)] from placebo were 377mL [293, 462] and 422 mL [337, 507], respectively; the difference between morning and evening dosing was -44mL [-125, 36]. Day 14 pre-treatment morning FEV1 differences [95% CI] from placebo were 403 mL [272, 533] and 496 mL [369, 624] after morning and evening dosing, respectively; the morning: evening treatment difference was -94 mL -[221, 34]. Pre-treatment evening FEV1 differences [95% CI] from placebo were 275mL [169, 380] and 309mL [205, 413] after morning and evening dosing, respectively; the morning:evening treatment difference was -34 mL [-138, 70]. FF/VI (morning or evening) produced rapid increases in PEF with the full effect apparent after the first dose and maintained throughout the 14-day treatment period. Conclusion: FF/VI 100/25 produces comparable improvements in lung function whether dosed in the morning or evening in subjects with persistent asthma. [ABSTRACT FROM AUTHOR] |
|
Copyright of Respiratory Medicine is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder